February 2023 Newsletter
New Animal Models
Humanized Immune-Checkpoint Mice |
|
| Catalog Number | Product |
| 111243 | B-hICAM3 mice |
| 111960 | B-hCD3E/h4-1BB/HLA-A2.1 mice |
| 112713 | B-hCD3EDG/hCD28/hTROP2 mice |
| 112712 | B-hCD3EDG/hCD28/hCD20 mice |
| 112259 | B-hNKP46 mice(CB-17 SCID) |
Humanized Cytokine Mice |
|
| Catalog Number | Product |
| 112400 | B-hIFNAR2 mice |
| 112156 | B-hFGF21 mice |
| 112523 | B-hANGPTL3 mice plus |
| 111199 | B-hLIF mice |
| 112706 | B-hPD-1/hPD-L1/hVEGFA mice |
Humanized GPCR Mice |
|
| Catalog Number | Product |
| 112547 | B-hCRTH2 mice plus |
Other Humanized Models |
|
| Catalog Number | Product |
| 111239 | B-hGPC1 mice |
Other Genetically Modified Mouse/Rat Models |
|
| Catalog Number | Product |
| 112357 | ROSA26 5xFAD KI mice |
New Cell lines
Other Cancer Cell Lines |
|
| Catalog Number | Product |
| 321871 | B-Tg(Luc) RKO |
| 321969 | B-Tg(Luc) A549 |
| 321974 | B-Tg(Luc) HCT 116 |
| 322228 | B-Luc CT26.WT |
Upcoming Event
Our webinar “Inflammatory Disease Modeling for Preclinical Studies” will be live at 1:00 PM EST on February 15th, 2023.
In this webinar, we will:
- Provide a brief overview on molecular mechanisms driving disease progression.
- Discuss modeling inflammatory diseases in wild-type and humanized mice, including psoriasis, atopic dermatitis, delayed type hypersensitivity, inflammatory bowel disease and experimental autoimmune encephalomyelitis.
- Evaluate in vivo efficacy of therapeutic agents in preclinical inflammatory disease mouse models.
Register now: https://biocytogen.zoom.us/webinar/register/WN_XuKRtn19TguF3zCNXta9UQ
News & Insights
RenNano® is the third member of the RenMiceTM family, joining RenMabTM and RenLite®. Together, Biocytogen’s three RenMiceTM platforms allow for the streamlined discovery and development of fully human monoclonal, bispecific/multispecific and single-domain antibodies.
Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM HiTS Platforms and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, announced an antibody collaboration, assignment and exclusive license agreement.
